1. Home
  2. CBL vs CAPR Comparison

CBL vs CAPR Comparison

Compare CBL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBL
  • CAPR
  • Stock Information
  • Founded
  • CBL 1978
  • CAPR 2005
  • Country
  • CBL United States
  • CAPR United States
  • Employees
  • CBL N/A
  • CAPR N/A
  • Industry
  • CBL Real Estate Investment Trusts
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CBL Real Estate
  • CAPR Health Care
  • Exchange
  • CBL Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • CBL 960.0M
  • CAPR 867.6M
  • IPO Year
  • CBL 1993
  • CAPR N/A
  • Fundamental
  • Price
  • CBL $29.51
  • CAPR $12.52
  • Analyst Decision
  • CBL
  • CAPR Strong Buy
  • Analyst Count
  • CBL 0
  • CAPR 7
  • Target Price
  • CBL N/A
  • CAPR $39.29
  • AVG Volume (30 Days)
  • CBL 178.3K
  • CAPR 1.5M
  • Earning Date
  • CBL 02-10-2025
  • CAPR 11-13-2024
  • Dividend Yield
  • CBL 5.14%
  • CAPR N/A
  • EPS Growth
  • CBL N/A
  • CAPR N/A
  • EPS
  • CBL 1.01
  • CAPR N/A
  • Revenue
  • CBL $523,580,000.00
  • CAPR $23,228,045.00
  • Revenue This Year
  • CBL N/A
  • CAPR N/A
  • Revenue Next Year
  • CBL N/A
  • CAPR $74.85
  • P/E Ratio
  • CBL $30.41
  • CAPR N/A
  • Revenue Growth
  • CBL N/A
  • CAPR 65.33
  • 52 Week Low
  • CBL $20.97
  • CAPR $3.52
  • 52 Week High
  • CBL $32.20
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • CBL 45.02
  • CAPR 34.06
  • Support Level
  • CBL $30.53
  • CAPR $13.00
  • Resistance Level
  • CBL $31.51
  • CAPR $20.75
  • Average True Range (ATR)
  • CBL 0.80
  • CAPR 1.67
  • MACD
  • CBL -0.27
  • CAPR -0.36
  • Stochastic Oscillator
  • CBL 8.95
  • CAPR 3.18

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a U.S.-based real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Share on Social Networks: